We then investigated the prognostic value of their expression in DLBCL in two independent cohorts of patients with newly-diagnosed DLBCL (accession number GSE10846 [21]): 233 patients treated with R-CHOP (rituximab-cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) (Lenz R-CHOP cohort) used as training cohort and 181 patients treated with CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) (Lenz CHOP cohort) used as validation cohort. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.